Medicaid Redeterminations and Renewals; Medicare Advantage; 340B Program
HR 2880 (118th Congress), Protecting Patients Against PBM Abuses Act, by Rep. Earl Carter (R-GA). To amend title XVIII of the Social Security Act to establish certain requirements for pharmacy benefit managers under Part D of the Medicare program.
HR 5380 (118th Congress), by Rep. John Sarbanes (D-MD). To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
HR 5385 (118th Congress), Medicare PBM Accountability Act, by Rep. Greg Landsman (D-OH). To amend title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D.
HR 5386 (118th Congress), Cutting Copays Act, by Rep. Morgan McGarvey (D-KY). To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare Part D cost-sharing reductions for low-income individuals.
HR 5388 (118th Congress), Supporting Innovation for Seniors Act, by Rep. Troy Balderson (R-OH). To amend title XVIII of the Social Security Act to provide coverage of certain technologies and medical devices under the Medicare program.
HR 5663 (118th Congress), ALS Better Care Act, by Rep. Janice Schakowsky (D-IL). To amend title XVIII of the Social Security Act to provide coverage of ALS-related services under the Medicare program for individuals diagnosed with amyotrophic lateral sclerosis.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
COVID Therapeutics; Cell and Gene Therapy; Step Therapy
HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars.
HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.
HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage.
Duration: January 1, 2014
to
present
General Issues: Medicare/Medicaid , Pharmacy , Taxation/Internal Revenue Code , Insurance , Health Issues , Budget/Appropriations
Spending: about $533,710 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Executive Office of the President (EOP), White House Office, Treasury - Dept of, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 18.
Original Filing: 301553064.xml
Lobbying Issues
Medicaid Redeterminations and Renewals; Medicare Advantage; 340B Program
HR 2880 (118th Congress), Protecting Patients Against PBM Abuses Act, by Rep. Earl Carter (R-GA). To amend title XVIII of the Social Security Act to establish certain requirements for pharmacy benefit managers under Part D of the Medicare program.
HR 5380 (118th Congress), by Rep. John Sarbanes (D-MD). To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
HR 5385 (118th Congress), Medicare PBM Accountability Act, by Rep. Greg Landsman (D-OH). To amend title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D.
HR 5386 (118th Congress), Cutting Copays Act, by Rep. Morgan McGarvey (D-KY). To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare Part D cost-sharing reductions for low-income individuals.
HR 5388 (118th Congress), Supporting Innovation for Seniors Act, by Rep. Troy Balderson (R-OH). To amend title XVIII of the Social Security Act to provide coverage of certain technologies and medical devices under the Medicare program.
HR 5663 (118th Congress), ALS Better Care Act, by Rep. Janice Schakowsky (D-IL). To amend title XVIII of the Social Security Act to provide coverage of ALS-related services under the Medicare program for individuals diagnosed with amyotrophic lateral sclerosis.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID Therapeutics; Cell and Gene Therapy; Step Therapy
HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars.
HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026.
HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301530306.xml
Lobbying Issues
Provider Directories; Medicaid Redeterminations; Draft Duals Legislation; IRA Copay Smoothing; MA Health Equity Index
HR 2880 (118th Congress), Protecting Patients Against PBM Abuses Act, by Rep. Earl Carter (R-GA). To amend title XVIII of the Social Security Act to establish certain requirements for pharmacy benefit managers under Part D of the Medicare program.
HR 4881 (118th Congress), by Rep. Nicole Malliotakis (R-NY). To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program.
HR 5380 (118th Congress), by Rep. John Sarbanes (D-MD). To amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage.
HR 5385 (118th Congress), Medicare PBM Accountability Act, by Rep. Greg Landsman (D-OH). To amend title XVIII of the Social Security Act to establish pharmacy benefit manager reporting requirements with respect to prescription drug plans and MA-PD plans under Medicare Part D.
HR 5386 (118th Congress), Cutting Copays Act, by Rep. Morgan McGarvey (D-KY). To amend title XVIII of the Social Security Act to provide for adjustments to the Medicare Part D cost-sharing reductions for low-income individuals.
HR 5388 (118th Congress), Supporting Innovation for Seniors Act, by Rep. Troy Balderson (R-OH). To amend title XVIII of the Social Security Act to provide coverage of certain technologies and medical devices under the Medicare program.
HR 5393 (118th Congress), by Rep. Morgan Griffith (R-VA). To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare Part D.
HR 5396 (118th Congress), Coverage Determination Clarity Act of 2023, by Rep. Larry Bucshon (R-IN). To amend title XVIII of the Social Security Act to prohibit Medicare local coverage determinations from restricting access to care.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
HR 6364 (118th Congress), Medicare Telehealth Privacy Act of 2023, by Rep. Troy Balderson (R-OH). To amend title XVIII of the Social Security Act to maintain certain telehealth flexibilities relating to provider privacy under the Medicare program.
S 1002 (118th Congress), No UPCODE Act, by Sen. Bill Cassidy (R-LA). To amend title XVIII of the Social Security Act to improve risk adjustment under Medicare Advantage.
S 2973 (118th Congress), Modernizing and Ensuring PBM Accountability Act, by Sen. Ron Wyden (D-OR). To amend titles XVIII and XIX of the Social Security Act to establish requirements relating to pharmacy benefit managers under the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines
HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars.
S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S 142 (118th Congress), Preserve Access to Affordable Generics and Biosimilars Act, by Sen. Amy Klobuchar (D-MN). To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
S 148 (118th Congress), Stop STALLING Act, by Sen. Amy Klobuchar (D-MN). To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns.
S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
S 954 (118th Congress), Affordable Insulin Now Act of 2023, by Sen. Raphael Warnock (D-GA). To provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals.
S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin.
S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301506304.xml
Lobbying Issues
Provider Directories; Medicaid Redeterminations; Draft Duals Legislation; IRA Copay Smoothing; MA Health Equity Index
HR 1613/S 1038 (118th Congress), Drug Price Transparency in Medicaid Act of 2023, by Rep. Earl Carter (R-GA) and Sen. Peter Welch (D-VT). To amend title XIX of the Social Security Act to improve transparency and prevent the use of spread pricing and related practices in the Medicaid program.
H.R.3284 (118th Congress), Providers and Payers COMPETE Act, by Rep. Michael Burgess (R-TX). To require the Secretary of Health and Human Services to submit an annual report on the impact of certain Medicare regulations on provider and payer consolidation.
H.R.5746 (118th Congress), Addressing Whole Health in Medicare Advantage Act, by Rep. Gus Bilirakis (R-FL). To amend title XVIII of the Social Security Act to expand the availability of supplemental benefits to certain Medicare Advantage enrollees.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Insulin Out of Pocket Charges; Prescription Drug Pricing; PBM Proposals; COVID Vaccines
S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin.
S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
S 2305 (118th Congress), Biosimilar Red Tape Elimination Act, by Sen. Mike Lee (R-UT). To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 19, 2023.
Original Filing: 301482713.xml
Lobbying Issues
Provider Directories; MA RADV Rule and Rate Notice; MA Advance Rate Notice and Prior Authorization Legislation; Medicaid Redeterminations; Medicare Wage Index Proposal; Medicaid Work Requirements; IRA Implementation
HR 1613/S1038 (118th Congress), Drug Price Transparency in Medicaid Act of 2023, by Rep. Earl Carter (R-GA) and Sen. Peter Welch (D-VT). To amend title XIX of the Social Security Act to improve transparency and prevent the use of spread pricing and related practices in the Medicaid program.
S 4750 (118th Congress), Restore Protections for Dialysis Patients Act, by Sen. Robert Menendez (D-NJ). To amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Insulin Out of Pocket Charges; Prescription Drug Pricing
S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
S 1067 (118th Congress), Ensuring Timely Access to Generics Act of 2023, by Sen. Jeanne Shaheen (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
S 1114 (118th Congress), Expanding Access to Low-Cost Generics Act of 2023, by Sen. Tina Smith (D-NH). To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
S 1269 (118th Congress), INSULIN Act of 2023, by Sen. Jeanne Shaheen (D-NH). To reduce the price of insulin and provide for patient protections with respect for the cost of insulin.
S 1339 (118th Congress), Pharmacy Benefit Manager Reform Act, by Sen. Bernie Sanders (I-VT). To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301460464.xml
Lobbying Issues
Medicare Advantage Rate Notice; Medicare Advantage Prior Authorization Legislation; Provider Directory Accuracy; MA RADV Rule and Rate Notice; Site Neutral Payments and Payment Accuracy; Medicaid Redeterminations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Insulin; Insulin Out of Pocket Charges; Prescription Drug Pricing
S 127 (118th Congress), Pharmacy Benefit Manager Transparency Act of 2023, by Sen. Maria Cantwell (D-WA). To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
S 142 (118th Congress), Preserve Access to Affordable Generics and Biosimilars Act, by Sen. Amy Klobuchar (D-MN). To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
S 148 (118th Congress), Stop STALLING Act, by Sen. Amy Klobuchar (D-MN). To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
S 150 (118th Congress), Affordable Prescriptions for Patients Act of 2023, by Sen. John Cornyn (R-TX). To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 18, 2023.
Original Filing: 301431752.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Medicare Advantage Prior Authorization; Medicare Advantage Provider Directories; Puerto Rico Medicaid Funding; Part D Reform
HR 3173 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Rep. Susan DelBene (D-WA). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
HR 8594 (117th Congress), Restore Protections for Dialysis Patients Act, by Rep. Yvette Clarke (D-NY). To amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act.
S 3018 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Sen. Roger Marshall (R-KS). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
S 4750 (117th Congress), Restore Protections for Dialysis Patients Act, by Sen. Robert Menendez (D-NJ). To amend title XVIII of the Social Security Act to clarify and preserve the breadth of the protections under the Medicare Secondary Payer Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Tests, Vaccines, and Treatments
The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301409531.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Prior Authorization; Medicare Advantage; Medicaid; Part D Reform
HR 2166 (117th Congress), Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021, by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs.
HR 3173 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Rep. Susan DelBene (D-WA). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
S 3018 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Sen. Roger Marshall (R-KS). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Testing and Vaccines
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 19, 2022.
Original Filing: 301384994.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Prior Authorization; Medicare Advantage; Medicaid; Part D Reform
HR 2166 (117th Congress), Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021, by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs.
HR 3173 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Rep. Susan DelBene (D-WA). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
S 3018 (117th Congress), Improving Seniors Timely Access to Care Act of 2021, by Sen. Roger Marshall (R-KS). Amends title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin; Coverage of Testing and Vaccines
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 19, 2022.
Original Filing: 301361863.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Medicaid; Part D Reform
HR 2166 (117th Congress), Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021, by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 19, 2022.
Original Filing: 301329429.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Part D Reform; Medicaid; Medicaid Coverage Gap; Telehealth/Audio-Only
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
HR 2166 (117th Congress), Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021, by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs.
HR 5260 (117th Congress), Reduced Costs and Continued Cures Act, by Rep. Scott Peters (D-CA). To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients out-of-pocket costs, and to ensure accountability to taxpayers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Rx Reform; Prescription Drugs; Prescription Drug Reform
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
HR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH). Amends the Public Health Service Act with respect to immunization system data modernization and expansion.
HR 2355 (117th Congress), Opioid Prescription Verification Act of 2021, by Rep. Rodney David (R-IL). To facilitate responsible, informed dispensing of controlled substances and other prescribed medications.
HR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL). Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Sequestration
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301311267.xml
Lobbying Issues
Medicare; Medicare Advantage Reform; Medicare Advantage Audio Only; Part D Reform; Medicaid; Medicaid Coverage Gap
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Requires the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
HR 2166 (117th Congress), Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021, by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs.
HR 4406 (117th Congress), Supporting Medicaid in the U.S. Territories Act of 2021, by Rep. Darren Soto (D-FL). To amend titles XI and XIX of the Social Security Act to provide increased financial support to the territories under the Medicaid program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform; Prescription Drugs; Prescription Drug Reform
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
HR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH). Amends the Public Health Service Act with respect to immunization system data modernization and expansion.
HR 2355 (117th Congress), Opioid Prescription Verification Act of 2021, by Rep. Rodney David (R-IL). To facilitate responsible, informed dispensing of controlled substances and other prescribed medications.
HR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL). Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Sequestration
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
S. Con. Res. 14 (117th Congress), by Sen. Bernie Sanders (I-VT). A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 16, 2021.
Original Filing: 301277267.xml
Lobbying Issues
Medicaid Maternal Health; Medicaid; Medicare Advantage Audio Only; Medicare; Medicare Advantage Reform; Part D Reform
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Requires the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
HR 2166 (117th Congress), by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs, and for other purposes.
HR 2170 (117th Congress), HAPI Act, by Rep. Darren Soto (D-FL). Amends title XIX of the Social Security Act to improve access to adult vaccines under Medicaid.
HR 2815 (117th Congress), BIOSIM Act, by Rep. Kurt Schrader (D-OR). Amends title XVIII of the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products.
HR 2846 (117th Congress), Ensuring Access to Lower Cost Medicines for Seniors Act of 2021, by Rep. David McKinley (R-WV). Amends title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary.
S 4840 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Sen. Pat Roberts (R-KS). Allows audio-only diagnoses made via telehealth to be used for purposes of determining risk adjustments to payments under Medicare Advantage, and requires payments for Medicare telehealth services furnished during the public health emergency relating to COVID-19 to be made in the same amounts as those for in-person services.
S 150 (117th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2021, by Sen. Catherine Cortez Masto (D-NV). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform; Prescription Drugs; Prescription Drug Reform
HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees.
HR 550 (117th Congress), Immunization Infrastructure Modernization Act of 2021, by Rep. Ann Kuster (D-NH). Amends the Public Health Service Act with respect to immunization system data modernization and expansion.
HR 951 (117th Congress), Maternal Vaccination Act, by Rep. Terri Sewell (D-AL). Directs the Secretary of Health and Human Services to carry out a national campaign to increase awareness of the importance of maternal vaccinations for the health of pregnant and postpartum individuals and their children.
HR 979 (117th Congress), Vaccine Fairness Act, by Rep. Angie Craig (D-MN). Directs the Secretary of Health and Human Services to submit to Congress a weekly report on COVID-19 vaccine distribution.
HR 1452 (117th Congress), by Rep. Dan Crenshaw (R-TX). Directs the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines.
HR 1978 (117th Congress), Protecting Seniors Through Immunization Act of 2021, by Rep. Ann Kuster (D-NH). Amends title XVIII of the Social Security Act to provide information regarding vaccines for seniors as part of the Medicare & You handbook and to ensure that the treatment of cost sharing for vaccines under Medicare Part D is consistent with the treatment of vaccines under Medicare Part B.
HR 2347 (117th Congress), Strengthening the Vaccines for Children Program Act of 2021, by Rep. Kim Schrier (D- WA). Amends title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program.
HR 2831 (117th Congress), Prompt Approval of Safe Generic Drugs Act, by Rep. Nanette Diaz Barragan (D-CA). Amends the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling.
HR 3013 (117th Congress), COVID Vaccine Transportation Access Act, by Rep. Nanette Diaz Barragan (D-CA). Authorizes the Secretary of Health and Human Services to award grants for removing transportation barriers to accessing vaccines for SARS-CoV-2, including booster vaccines, for individuals from low-income communities, minority communities, or other communities in which transportation poses a barrier to health care access.
HR 3655 (117th Congress), Vaccine Injury Compensation Modernization Act of 2021, by Rep. Lloyd Doggett (D-TX). Amends the Public Health Service Act to make updates to the Vaccine Injury Compensation Program.
HR 3742 (117th Congress), Vaccine INFO Act, by Rep. Gus Bilirakis (R-FL). Requires the Secretary of Health and Human Services to issue revised regulations to require the dissemination of information on ACIP recommended immunizations to staff of nursing facilities.
HR 3743 (117th Congress), Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, by Rep. Richard Hudson (R-NC). Increases funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
ACA Tax Credits; APTC
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301260854.xml
Lobbying Issues
Medicaid Maternal Coverage; Medicare Advantage Audio Only; Medicaid FMAP; Medicare; Medicare Advantage
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
HR 2166 (117th Congress), by Rep. Terri Sewell (D-AL). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans and PACE programs, and for other purposes.
S 4840 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Sen. Pat Roberts (R-KS). Allows audio-only diagnoses made via telehealth to be used for purposes of determining risk adjustments to payments under Medicare Advantage, and requires payments for Medicare telehealth services furnished during the public health emergency relating to COVID-19 to be made in the same amounts as those for in-person services.
S 150 (117th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2021, by Sen. Catherine Cortez Masto (D-NV). Amends title XVIII of the Social Security Act to require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans, and for other purposes.
S 748 (117th Congress), Medicare Sequester Relief Act, by Rep. Jeanne Shaheen (D-NH). Provides for an extension of the temporary suspension of Medicare sequestration during the COVID-19 public health emergency.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
ACA Tax Credits
HR 1868 (117th Congress), by Rep. John Yarmuth (D-KY). Makes several budgetary and technical changes to provisions under Medicare and Medicaid, including continuing to exempt Medicare from sequestration until December 31, 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 19, 2021.
Original Filing: 301234854.xml
Lobbying Issues
Medicare Advantage Audio Only; Medicaid Maternal Coverage
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
S 4840 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Sen. Pat Roberts (R-KS). Allows audio-only diagnoses made via telehealth to be used for purposes of determining risk adjustments to payments under Medicare Advantage, and requires payments for Medicare telehealth services furnished during the public health emergency relating to COVID-19 to be made in the same amounts as those for in-person services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 15, 2020.
Original Filing: 301210802.xml
Lobbying Issues
Medicare Advantage; Medicaid Expansion; Medicaid; Privacy; Medicare Prescription Drug Prices; CMS; CHIP, MACRA; Provider Funding; Medicaid FMAP Increase; Coronavirus Medicaid Response; Rate Notice and Call Letter; Star Ratings
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). Establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
HR 7659 (116th Congress), Ensuring Parity in MA for Audio-Only Telehealth Act of 2020, by Rep. Terri Sewell (D-AL). Require the inclusion of certain audio-only diagnoses in the determination of risk adjustment for Medicare Advantage plans.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 17, 2020.
Original Filing: 301190756.xml
Lobbying Issues
Medicare Advantage; Medicaid Expansion; Medicaid; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices; CMS; Generic Drugs (CREATES Act); Drug Approval; HELP Cost Reduction Package; CHIP, MACRA; Provider Funding; Medicaid FMAP Increase; Coronavirus Medicaid Response; Rate Notice and Call Letter
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). Establish requirements with respect to the use of prior authorization under Medicare Advantage plans.
HR 5534 (116th Congress), Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, by Rep. Ron Kind (D-WI). Provide for extended months of Medicare coverage of immunosuppressive drugs for kidney transplant patients.
HR 5582 (116th Congress), Parental Accessibility Rights for Emergency and Negligent Treatment Act, by Rep. Gregory Murphy (R-NC). Expands the scope of advance directive policies and related disclosures for providers under Medicaid and the Children's Health Insurance Program (CHIP).
HR 5693 (116th Congress), Primary Health Services Enhancement Act, by Rep. Ron Kind (D-WI). Expand Medicare Rural Health Clinic Services and Federally Qualified Health Center Services to include physical therapy services.
HR 5741 (116th Congress), Strengthening Innovation in Medicare and Medicaid Act, by Rep. Terri Sewell (D-AL). Clarify parameters for model testing and add accountability to model expansion under the Center for Medicare and Medicaid Innovation.
HR 5833 (116th Congress), by Rep. Bob Latta (R-OH). Permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain.
HR 5882 (116th Congress), GENE Therapy Payment Act, by Rep. Kurt Schrader (D-OR). Provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements.
HR 5897 (116th Congress), Preventing Abuse and Neglect of Vulnerable Americans Act of 2020, by Rep. Ruben Gallego (D-AZ). Requires the Centers for Medicare & Medicaid Services (CMS) to publish specified information on its website relating to deficiencies of Medicaid intermediate care facilities for individuals with intellectual disabilities, including information regarding inspections, complaints, and administrative actions.
HR 5900 (116th Congress), Accelerating Kids' Access to Care Act, by Rep. Joseph Kennedy (D-MA). Requires state Medicaid programs to establish a process through which qualifying out-of-state providers may enroll as participating providers without undergoing additional screening requirements.
HR 6098 (116th Congress), by Rep. Nanette Diaz Barragan (D-CA). Allow States to expand income eligibility standards under the Childrens Health Insurance Program.
HR 6147 (116th Congress), Help Extend Auditory Relief (HEAR) Act of 2020, by Rep. Matt Cartwright (D-PA). Provide coverage under the Medicare program of hearing aids and related hearing services.
HR 6159 (116th Congress), Kids Access to Primary Care Act of 2020, by Rep. Kim Schrier (D-WA). Renew the application of the Medicare payment rate floor to primary care services furnished under the Medicaid program.
HR 6179 (116th Congress), Increasing Access to Biosimilars Act of 2020, by Rep. Tony Cardenas (D-CA). Require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
HR 6214 (116th Congress), by Rep. Ron Kind (D-WI). Provide for coverage of testing for COVID-19 at no cost sharing under the Medicare Advantage program.
HR 6218 (116th Congress), Preserving Patient Access to Home Infusion Act, by Rep. Eliot Engel (D-NY). Clarify congressional intent and preserve patient access to home infusion therapy under the Medicare program.
HR 6263 (116th Congress), by Rep. John Sarbanes (D-MD). Waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19.
HR 6273 (116th Congress), Protecting Vulnerable Americans in Times of Crisis Act of 2020, by Rep. G. K. Butterfield (D-NC). Increase allotments under the Medicaid program for territories of the United States, to provide for a temporary increase in the Federal medical assistance percentage for States under the Medicaid program.
HR 6281 (116th Congress), Medicare Wage Index Parity Act of 2020, by Rep. Bill Pascrell (D-NJ). Provides statutory authority for, and extends, a specified methodology used to calculate the minimum Medicare hospital wage index for all-urban states.
HR 6282 (116th Congress), Commission on America's Medical Security Act, by Rep. Raul Ruiz (D-CA). Establish a commission to assess, evaluate, and address the dependence of the United States on medications, devices, and medical equipment from foreign countries.
HR 6336 (116th Congress), Increasing Hospital Capacity to Fight the Coronavirus Act of 2020, by Rep. Dan Bishop (R-NC). Provide a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency.
HR 6486 (116th Congress), Care for COVID-19 Act 2.0, by Rep. Raul Ruiz (D-CA). Require the Secretary of Health and Human Services to establish a special enrollment period during the COVID-19 emergency period, to require the Secretary to carry out outreach and educational activities for such special enrollment period, to require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage without any cost sharing for certain items and services furnished during any portion of such emergency period.
HR 6487 (116th Congress), Advancing Connectivity during the Coronavirus to Ensure Support for Seniors Act, by Rep. Jan Schakowsky (D-IL). Increase the ability of nursing facilities to access telehealth services and obtain technologies to allow virtual visits during the public health emergency relating to an outbreak of coronavirus disease 2019 (COVID-19).
HR 6583 (116th Congress), by Rep. Chrissy Houlahan (D-PA). Establish a risk corridor program for Medicare Advantage plans during the COVID-19 emergency.
HR 6616 (116th Congress), Stronger Medicaid Response to the COVID-19 Pandemic Act, by Rep. Tony Cardenas (D-CA). Allows COVID-19 vaccines and treatment, as well as treatment for conditions that may complicate COVID-19 treatment, for uninsured individuals to be covered under Medicaid during the public health emergency.
HR 6640 (116th Congress), Medicare Advantage COVID Treatment Act, by Rep. Debbie Mucarsel-Powell (D-FL). Requires Medicare Advantage (MA) plans to cover specified treatment services relating to COVID-19 without cost-sharing during the public health emergency.
HR 6649 (116th Congress), Lower Drug Costs for Seniors During COVID-19 Act of 2020, by Rep. Janice Schakowsky (D-IL). Requires the Centers for Medicare & Medicaid Services to establish a process for prescription drug plans under Medicare and Medicare Advantage to allow enrollees to make coinsurance payments in periodic installments, if the enrollee chooses to obtain the entire prescribed supply of a covered drug in a single fill.
HR 6674 (116th Congress), Medicare Crisis Program Act of 2020, by Rep. Pramila Jayapal (D-WA). Ensure access to affordable, comprehensive health insurance benefits for certain uninsured individuals during the COVID-19 emergency, and to ensure adequate coverage of treatments for COVID-19 under the Medicare and Medicaid programs and under group health plans and group or individual health insurance coverage.
HR 6698 (116th Congress), Quality Care for Nursing Home Residents and Workers During COVID-19 Act of 2020, by Rep. Jan Schakowsky (D-IL). Improve the quality of care in skilled nursing facilities under the Medicare program and nursing facilities under the Medicare program during the COVID-19 emergency period.
HR 6739 (116th Congress), Ensuring Seniors' Access to COVID Treatments Act, by Rep. Sean Casten (D-IL). Requires prescription drug plans under Medicare and Medicare Advantage to cover drugs that are approved to treat COVID-19 without cost-sharing during the public health emergency.
HR 6753 (116th Congress), Rural Community Hospital Demonstration Extension Act of 2020, by Rep. Abby Finkenauer (D-IA). Amend the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to extend the rural community hospital demonstration program.
HR 6837 (116th Congress), Medicare Accelerated and Advance Payments Improvement Act of 2020, by Rep. Bradley Scott Schneider (D-IL). Modify the accelerated and advance payment programs under parts A and B of the Medicare program during the COVID-19 emergency.
HR 6971 (116th Congress), Medical Nutrition Therapy Act of 2020, by Rep. Eliot Engel (D-NY). Expand the availability of medical nutrition therapy services under the Medicare program.
HR 7062 (116th Congress), Affordable Insulin for the COVID-19 Emergency Act, by Rep. Maxine Waters (D-CA). Eliminate cost-sharing with respect to coverage of insulin as a covered part D drug and associated medical supplies and to provide mail order access to insulin and such supplies under the Medicare program during the COVID-19 emergency period.
HR 7127 (116th Congress), by Rep. G. K. Butterfield (D-NC). Makes technical amendments to the separate payment under the Medicare program for disposable negative pressure wound therapy devices.
HR 7154 (116th Congress), Outpatient Therapy Modernization and Stabilization Act, by Rep. Brendan Boyle (D-PA). Improve and ensure ongoing Medicare beneficiary access to outpatient therapy services.
HR 7292 (116th Congress), COVID-19 Hospital and Health Provider Loan Forgiveness Act of 2020, by Rep. Marcy Kaptur (D-OH). Provide for forgiveness of certain accelerated and advance payments under parts A and B of the Medicare program.
HR 7323 (116th Congress), Medicare Mental Health Inpatient Equity Act of 2019, by Rep. Paul Tonko (D-NY). Eliminate the 190-day lifetime limit on inpatient psychiatric hospital services under the Medicare Program.
HR 7338 (116th Congress), by Rep. Liz Cheney (R-WY). Permit the Secretary of Health and Human Services to waive requirements relating to the furnishing of telehealth services under the Medicare program.
HR 7391 (116th Congress), by Rep. Mikie Sherrill (D-NJ). Remove certain geographic and originating site restrictions on the furnishing of telehealth services under the Medicare program.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301173684.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; Rate Notice and Call Letter; Medicare Part D; Part D Prescription Drug Rebates; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices; CMS Program Integrity Rule; Generic Drugs (CREATES Act)
HR 3 (116th Congress), Lower Drug Costs Now Act of 2019, by Rep. Frank Pallone, Jr. (D-NJ). To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
HR 275 (116th Congress), Medicare Prescription Drug Price Negotiation Act of 2019, by Rep. Peter Welch (D-VT). To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.
HR 448 (116th Congress), Medicare Drug Price Negotiation Act, by Rep. Elijah Cummings (D-MD). To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
HR 1046 (116th Congress), Medicare Negotiation and Competitive Licensing Act of 2019, by Rep. Lloyd Doggett (D-TX). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
HR 1781 (116th Congress), Payment Commission Data Act of 2019, by Rep. Earl Carter (D-GA). To amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). To amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans, and for other purposes.
HR 4629 (116th Congress), Star Rating for Biosimilars Act, by Rep. Paul Tonko (D-NY). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to add a new set of measures to the 5-star rating system under the Medicare Advantage program in order to encourage increased access to biosimilar biological products.
HR 5534 (116th Congress), Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019, by Rep. Ron Kind (D-WI). To amend title XVIII of the Social Security Act to provide for extended months of Medicare coverage of immunosuppressive drugs for kidney transplant patients, and for other purposes.
HR 5693 (116th Congress), Primary Health Services Enhancement Act, by Rep. Ron Kind (D-WI). To amend title XVIII of the Social Security Act to expand Medicare Rural Health Clinic Services and Federally Qualified Health Center Services to include physical therapy services.
HR 5741 (116th Congress), Strengthening Innovation in Medicare and Medicaid Act, by Rep. Terri Sewell (D-AL). To amend title XI of the Social Security Act to clarify parameters for model testing and add accountability to model expansion under the Center for Medicare and Medicaid Innovation, and for other purposes.
HR 5833 (116th Congress), by Rep. Bob Latta (R-OH). To amend title XVIII of the Social Security Act to permit the use of certain psychological evaluation via telehealth for Medicare coverage of neurostimulation services for the treatment of chronic pain.
HR 6147 (116th Congress), Help Extend Auditory Relief (HEAR) Act of 2020, by Rep. Matt Cartwright (D-PA). To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of hearing aids and related hearing services.
HR 6179 (116th Congress), Increasing Access to Biosimilars Act of 2020, by Rep. Tony Cardenas (D-CA). To require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
HR 6218 (116th Congress), Preserving Patient Access to Home Infusion Act, by Rep. Eliot Engel (D-NY). To amend title XVIII of the Social Security Act to clarify congressional intent and preserve patient access to home infusion therapy under the Medicare program, and for other purposes.
HR 6263 (116th Congress), by Rep. John Sarbanes (D-MD). To amend title XVIII of the Social Security Act to waive cost sharing under the Medicare program for certain visits relating to testing for COVID-19.
HR 6273 (116th Congress), Protecting Vulnerable Americans in Times of Crisis Act of 2020, by Rep. G. K. Butterfield (D-NC). To amend title XI of the Social Security Act to increase allotments under the Medicaid program for territories of the United States, to provide for a temporary increase in the Federal medical assistance percentage for States under the Medicaid program, and for other purposes.
HR 6336 (116th Congress), Increasing Hospital Capacity to Fight the Coronavirus Act of 2020, by Rep. Dan Bishop (R-NC). To amend title XI of the Social Security Act to provide for a waiver of payment reductions under the Medicare and Medicaid programs for certain nonapproved capital expenditures undertaken by health care facilities during the COVID-19 emergency.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 16, 2020.
Original Filing: 301108020.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D; Part D Donut Hole; Prescription Drug Rebates; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices
HR 3 (116th Congress), Lower Drug Costs Now Act of 2019, by Rep. Frank Pallone, Jr. (D-NJ). To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
HR 275 (116th Congress), Medicare Prescription Drug Price Negotiation Act of 2019, by Rep. Peter Welch (D-VT). To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.
HR 448 (116th Congress), Medicare Drug Price Negotiation Act, by Rep. Elijah Cummings (D-MD). To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
HR 1046 (116th Congress), Medicare Negotiation and Competitive Licensing Act of 2019, by Rep. Lloyd Doggett (D-TX). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
HR 1781 (116th Congress), Payment Commission Data Act of 2019, by Rep. Earl Carter (D-GA). To amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). To amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans, and for other purposes.
HR 4629 (116th Congress), Star Rating for Biosimilars Act, by Rep. Paul Tonko (D-NY). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to add a new set of measures to the 5-star rating system under the Medicare Advantage program in order to encourage increased access to biosimilar biological products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health Insurance Tax (HIT Tax)
HR 1398 (116th Congress), Health Insurance Tax Relief Act of 2019, by Rep. Ami Bera (D-CA). To delay the reimposition of the annual fee on health insurance providers until after 2021.
S 172 (116th Congress), Health Insurance Tax Relief Act of 2019, by Sen. Cory Gardner (R-CO). To delay the reimposition of the annual fee on health insurance providers until after 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 17, 2019.
Original Filing: 301068141.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D; Part D Donut Hole; Prescription Drug Rebates; Medicare Data Sharing; Privacy; Medicare Prescription Drug Prices
HR 3 (116th Congress), Lower Drug Costs Now Act of 2019, by Rep. Frank Pallone, Jr. (D-NJ). To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.
HR 275 (116th Congress), Medicare Prescription Drug Price Negotiation Act of 2019, by Rep. Peter Welch (D-VT). To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries.
HR 448 (116th Congress), Medicare Drug Price Negotiation Act, by Rep. Elijah Cummings (D-MD). To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
HR 1046 (116th Congress), Medicare Negotiation and Competitive Licensing Act of 2019, by Rep. Lloyd Doggett (D-TX). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.
HR 1781 (116th Congress), Payment Commission Data Act of 2019, by Rep. Earl Carter (D-GA). To amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
HR 3107 (116th Congress), Improving Seniors Timely Access to Care Act of 2019, by Rep. Suzan DelBene (D-WA). To amend title XVIII of the Social Security Act to establish requirements with respect to the use of prior authorization under Medicare Advantage plans, and for other purposes.
HR 4629 (116th Congress), Star Rating for Biosimilars Act, by Rep. Paul Tonko (D-NY). To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to add a new set of measures to the 5-star rating system under the Medicare Advantage program in order to encourage increased access to biosimilar biological products.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Health Insurance Tax (HIT Tax)
HR 1398 (116th Congress), Health Insurance Tax Relief Act of 2019, by Rep. Ami Bera (D-CA). To delay the reimposition of the annual fee on health insurance providers until after 2021.
S 172 (116th Congress), Health Insurance Tax Relief Act of 2019, by Sen. Cory Gardner (R-CO). To delay the reimposition of the annual fee on health insurance providers until after 2021.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 17, 2019.
Original Filing: 301047784.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D; Part D Donut Hole; Prescription Drug Rebates; Medicare Data Sharing; Privacy
HR 1781 (116th Congress), Payment Commission Data Act of 2019, by Rep. Earl Carter (D-GA). To amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 17, 2019.
Original Filing: 301026906.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D; Part D Donut Hole; Prescription Drug Rebates; Medicare Data Sharing; Privacy
HR 1781 (116th Congress), Payment Commission Data Act of 2019, by Rep. Earl Carter (D-GA). To amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 18, 2019.
Original Filing: 301008208.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D; Patient's Act (Dialysis); Part D Donut Hole; Prescription Drug Rebates; ACE Kid's Act
HR 6 Introduced June 13, 2018 by Greg Walden (R-OR). The SUPPORT for Patients and Communities Act includes Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, protecting communities, and bolstering efforts to combat illicit synthetic drugs like fentanyl. The policies contained in the legislation were advanced through regular order by the House Energy and Commerce Committee and the Ways and Means Committee.
HR 3325 Introduced July 20, 2017 by Joe Barton (R-TX). This bill amends title XIX of the Social Security Act to provide states with the option of providing coordinated care for children with complex medical conditions through a health home, and for other purposes.
HR 4143 Introduced October 26, 2017 by Jason Smith (R-MO). The Dialysis Patients Demonstration Act of 2017 establishes a demonstration program to provide integrated care for Medicare beneficiaries with end-stage renal disease, and for other purposes.
HR 6478 Introduced July 23, 2018 by John Sarbanes (D-MD). The Biosimilars Competition Act of 2018 enhances competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding biologic and biosimilar products, and for other purposes.
S 2554 Introduced March 14, 2018 by Susan Collins (R-ME). The Patient Right to Know Drug Price Act of 2018. Americans overspend by an estimated $135 million on prescriptions through their insurance, in cases where their drugs would cost less out of pocket. Yet pharmacists are often under gag orders from telling customers about that discrepancy. This bill would end this practice.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 18, 2018.
Original Filing: 300988954.xml
Lobbying Issues
Medicare Advantage; Medicare Prior Authorization; Medicaid Rebates; Medicaid Expansion; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicare Part D
HR 6 Introduced June 13, 2018 by Greg Walden (R-OR). The SUPPORT for Patients and Communities Act includes Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, protecting communities, and bolstering efforts to combat illicit synthetic drugs like fentanyl. The policies contained in the legislation were advanced through regular order by the House Energy and Commerce Committee and the Ways and Means Committee.
HR 3325 Introduced July 20, 2017 by Joe Barton (R-TX). This bill amends title XIX of the Social Security Act to provide states with the option of providing coordinated care for children with complex medical conditions through a health home, and for other purposes.
HR 4143 Introduced October 26, 2017 by Jason Smith (R-MO). The Dialysis Patients Demonstration Act of 2017 establishes a demonstration program to provide integrated care for Medicare beneficiaries with end-stage renal disease, and for other purposes.
HR 6478 Introduced July 23, 2018 by John Sarbanes (D-MD). The Biosimilars Competition Act of 2018 enhances competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding biologic and biosimilar products, and for other purposes.
S 2554 Introduced March 14, 2018 by Susan Collins (R-ME). The Patient Right to Know Drug Price Act of 2018. Americans overspend by an estimated $135 million on prescriptions through their insurance, in cases where their drugs would cost less out of pocket. Yet pharmacists are often under gag orders from telling customers about that discrepancy. This bill would end this practice.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300975767.xml
Lobbying Issues
Medicare Advantage; CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medicaid; Opioids; Medicare Part D
HR 2575 Introduced May 19, 2017 by Raul Ruiz (R-CA). To amend title XVIII of the Social Security Act to establish a system to educate individuals approaching Medicare eligibility, to simplify and modernize the eligibility enrollment process, and for other purposes.
HR 3780 Introduced September 14, 2017 by Richard Hudson (R-NC). The Air Ambulance Quality and Accountability Act amends title XVIII of the Social Security Act to provide under the Medicare program for conditions of participation, reporting requirements, and a quality program with respect to air ambulance services.
HR 3921 Introduced October 3, 2017 by Michael Burgess (R-TX). The HEALTHY KIDS Act extends funding for the Childrens Health Insurance Program, and for other purposes.
HR 1148 Introduced February 16, 2017 by Morgan Griffith (R-VA). The FAST Act of 2017 amends title XVIII of the Social Security Act to expand access to telehealth-eligible stroke services under the Medicare program.
HR 3192 Introduced July 12, 2017 by Joseph Kennedy (D-MA). The CHIP Mental Health Parity Act amends title XXI of the Social Security Act to ensure access to mental health services for children under CHIP, and for other purposes.
HR 6 Introduced June 13, 2018 by Greg Walden (R-OR). The SUPPORT for Patients and Communities Act includes Medicaid, Medicare, and public health reforms to combat the opioid crisis by advancing treatment and recovery initiatives, improving prevention, protecting communities, and bolstering efforts to combat illicit synthetic drugs like fentanyl. The policies contained in the legislation were advanced through regular order by the House Energy and Commerce Committee and the Ways and Means Committee.
HR 5806 Introduced May 15, 2018 by Michael Burgess (R-TX). The 21st Century Tools for Pain and Addiction Treatment Act requires the Secretary of Health and Human Services to issue guidance with respect to the expedited approval of certain drugs, and for other purposes.
HR 5811 Introduced May 15, 2018 by Jerry McNerney (D-CA). The Long-Term Opioid Efficacy Act of 2018 amends the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes.
HR 5715 Introduced May 9, 2018 by James Renacci (R-OH). The Strengthening Partnerships to Avoid Opioid Abuse Act amends title XVIII of the Social Security Act to provide for certain program integrity transparency measures under Medicare Parts C and D.
HR 5716 Introduced May 9, 2018 by Peter Roskam (R-IL). The COMPASS Act amends title XVIII of the Social Security Act to provide for certain program integrity transparency measures under Medicare Parts C and D.
HR 5590 Introduced April 24, 2018 by Adam Kinzinger (R-IL). The Opioid Addiction Action Plan requires the Secretary of Health and Human Services to provide for an action plan on recommendations for changes under the Medicare and Medicaid programs to prevent opioid addiction and enhance access to medication assisted treatment, and for other purposes.
HR 5603 Introduced April 24, 2018 by Doris Matsui (D-CA). The Access to Telehealth Services for Substance Use Disorders Act amends title XVIII of the Social Security Act to provide the Secretary of Health and Human Services authority to waive certain Medicare telehealth requirements in the case of certain treatment of an opioid use disorder or a co-occurring mental health disorder.
HR 5798 Introduced May 15, 2018 by Larry Bucshon (R-IN). The Opioid Screening and Chronic Pain Management Alternatives for Seniors Act amends title XVIII of the Social Security Act to require a review of current opioid prescriptions for chronic pain and screening for opioid use disorder to be included in the Welcome to Medicare initial preventive screening examination.
HR 5580 Introduced April 23, 2018 by Ann Kuster (D-NH). The STOP Fentanyl Deaths Act of 2018 authorizes the Secretary of Health and Human Services to conduct programs to address the usage of illicit drugs, particularly fentanyl, and for other purposes.
HR 5809 Introduced May 15, 2018 by Scott Peters (D-CA). The Postoperative Opioid Prevention Act of 2018 amends title XVIII of the Social Security Act to encourage the use of non-opioid analgesics for the management of post-surgical pain under the Medicare program, and for other purposes.
HR 5795 Introduced May 15, 2018 by Earl Blumenauer (D-OR). The Overdose Prevention and Patient Safety Act amends the PHSA to protect the confidentiality of substance use disorder patient records.
HR 5009 Introduced February 13, 2018 by Tim Walberg (R-MI). Jessies Law ensures medical professionals have access to a consenting patients complete health information when making treatment decisions by requiring the Department of Health and Human Services to develop and annually disseminate best practices regarding the prominent display of substance use disorder (SUD) history in records of patients who have previously provided this information to a health care provider.
HR 5685 Introduced May 7, 2018 by John Faso (R-NY). The Medicare Opioid Safety Education Act of 2018 directs CMS to compile education resources for beneficiaries regarding opioid use, pain management, and alternative pain management treatments, and include those resources in the Medicare and You handbook.
HR 5675 Introduced May 3, 2018 by Gus Bilirakis (R-FL). This bill requires Medicare prescription drug plan (PDP) sponsors to establish drug management programs for at-risk beneficiaries for plan years beginning on or after January 1, 2021. Current law authorizes, but does not require, PDP sponsors to establish such programs.
HR 5686 Introduced May 7, 2018 by Erik Paulsen (R-MN). The Medicare Clear Health Options in Care for Enrollees Act of 2018 amends title XVIII of the Social Security Act to require prescription drug plans under Medicare Part D to include information on the adverse effects of opioid overutilization and of coverage for nonpharmacological therapies and non-opioid medications or devices used to treat pain.
HR 5684 Introduced May 7, 2018 by Mike Kelly (R-PA). The Protecting Seniors from Opioid Abuse Act amends title XVIII of the Social Security Act to expand eligibility for medication therapy management programs established under Medicare Part D to include certain individuals who are at risk for prescription drug abuse.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 19, 2018.
Original Filing: 300950220.xml
Lobbying Issues
CHIP Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medigap; Site Neutral Payments; Medicare Advantage; SNPs (Special Needs Plans); Medicaid Provider Enrollment
H.R.1148 - 115th Congress (2017-2018). FAST Act of 2017. Sponsor: Rep. Griffith, H. Morgan [R-VA-9] (Introduced 02/16/2017)
H.R.4998 - 115th Congress (2017-2018). Health Insurance for Former Foster Youth Act. Sponsor: Rep. Bass, Karen [D-CA-37] (Introduced 02/13/2018)
H.R.4005 - 115th Congress (2017-2018). Medicaid Reentry Act. Sponsor: Rep. Tonko, Paul [D-NY-20] (Introduced 10/10/2017)
H.R.1925 - 115th Congress (2017-2018). At-Risk Youth Medicaid Protection Act of 2017. Sponsor: Rep. Cardenas, Tony [D-CA-29] (Introduced 04/05/2017)
H.R.3331 - 115th Congress (2017-2018). To amend title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology. Sponsor: Rep. Jenkins, Lynn [R-KS-2] (Introduced 07/20/2017)
H.R.3528 - 115th Congress (2017-2018). Every Prescription Conveyed Securely Act. Sponsor: Rep. Clark, Katherine M. [D-MA-5] (Introduced 07/28/2017)
H.R.4841 - 115th Congress (2017-2018). Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018. Sponsor: Rep. Schweikert, David [R-AZ-6] (Introduced 01/18/2018)
H.R.3192 - 115th Congress (2017-2018). CHIP Mental Health Parity Act. Sponsor: Rep. Kennedy, Joseph P., III [D-MA-4] (Introduced 07/12/2017)
H.R.2575 - 115th Congress (2017-2018). BENES Act of 2017. Sponsor: Rep. Ruiz, Raul [D-CA-36] (Introduced 05/19/2017)
H.R.3921 - 115th Congress (2017-2018). HEALTHY KIDS Act. Sponsor: Rep. Burgess, Michael C. [R-TX-26] (Introduced 10/03/2017)
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300928086.xml
Lobbying Issues
CHIP Reform; Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); Rate Notice and Call Letter; Medigap; Site Neutral Payments; Medicare Advantage; Special Needs Plans (SNPs)
H.R. 3921 - 115th Congress (2017-2018) HEALTHY KIDS Act. Sponsor: Rep. Michael Burgess (R-TX)
H.R. 1148 - 115th Congress (2017-2018) FAST Act of 2017. Sponsor: Rep. H. Morgan Griffith (R-VA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 19, 2017.
Original Filing: 300908802.xml
Lobbying Issues
Medigap, Medicare Advantage, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Rate Notice and Call Letter, Third Party Payment of Premiums
HR 2575 Introduced May 19, 2017 by Raul Ruiz (R-CA) To amend title XVIII of the Social Security Act to establish a system to educate individuals approaching Medicare eligibility, to simplify and modernize the eligibility enrollment process, and for other purposes.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 20, 2017.
Original Filing: 300893360.xml
Lobbying Issues
Medigap, Medicare Advantage, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Rate Notice and Call Letter, Third Party Payment of Premiums
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 18, 2017.
Original Filing: 300868142.xml
Lobbying Issues
Medigap, Medicare Advantage, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Rate Notice and Call Letter
HR 1290 Improving Access to Mental Health Introduced March 1, 2017 by Barbara Lee (D-CA). To amend title XVIII of the Social Security Act to improve access to mental health services under the Medicare program.
HR 1298 CT Colonography Screening for Colorectal Cancer Act of 2017 Introduced March 1, 2017 by Brad Wenstrup (R-OH). To amend title XVIII of the Social Security Act to cover screening computed tomography colonography as a colorectal cancer screening test under the Medicare program.
HR 1361 Introduced March 2, 2017 by Lee Zeldin (R-NY). To amend title XVIII of the Social Security Act to provide for the non-application of Medicare competitive acquisition rates.
HR 1394 Introduced March 7, 2017 by Susan Brooks (R-IN). To amend title XIX of the Social Security Act to provide states with flexibility with respect to providing coverage for nonemergency transportation under Medicaid.
HR 1395 MACPAC Improvement Act of 2017 Introduced March 8, 2017 by Michael Burgess (R-TX). To amend title XIX of the Social Security Act to improve the Medicaid and CHIP Payment and Access Commission (MACPAC).
HR 1421 Improving Access to Medicare Act of 2017 Introduced March 8, 2017 by Joe Courtney (D-CT). To amend title XVIII of the Social Security Act to count a period of receipt of outpatient observation services in a hospital toward satisfying the 3-day inpatient hospital stay requirement for coverage of skilled nursing facility services under Medicare.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
GuideWell Mutual Holding Corporation amended a lobbying report for in-house lobbying in Q42016 on Jan. 20, 2017
Original Filing: 300853688.xml
Lobbying Issues
HR 5506 Introduced June 15, 2016 by Todd Young (R-IN) to amend title XVIII of the Social Security to establish a demonstration program to provide integrated care for Medicare beneficiaries with end-stage renal disease, and for other purposes.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 18, 2017.
Original Filing: 300849392.xml
Lobbying Issues
HR 5506 Introduced June 15, 2016 by Todd Young (R-IN) to amend title XVIII of the Social Security to establish a demonstration program to provide integrated care for Medicare beneficiaries with end-stage renal disease, and for other purposes.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300835416.xml
Lobbying Issues
Medicare and Medicaid issues, Medigap issues, Medicare Advantage, CHIP reform, chronic care reform
HR 2488 Medicare Beneficiary Preservation of Choice Act of 2015 Introduced May 21, 2015 by Keith Rothfus (R-PA) This bill amends title XVIII (Medicare) of the Social Security Act to expand and modify enrollment and disenrollment options for Medicare Advantage (MA) eligible individuals. Specifically, the bill extends the annual period in which an individual enrolled in MA may elect to instead receive benefits under the original Medicare fee-for-service (FFS) program as well as elect to change qualified prescription drug coverage. Furthermore, any MA-eligible individual (weather or not enrolled in MA) may once per period change a previous election with respect to receiving benefits through MA or Medicare FFS, including changing from one MA plan to another. Unsolicited marketing during this period is prohibited.
HR 2895 Introduced June 25, 2015 by Mike Pompeo (R-KS) Medicare Patient Access to Cancer Treatment Act of 2015 To amend title XVIII of the Social Security Act to establish payment parity under the Medicare program for ambulatory cancer care services furnished in the hospital outpatient department and the physician office setting.
HR 3716 Introduced October 8, 2015 by Larry Bucshon (R-IN) To amend title XIX of the Social Security Act to require States to provide to the Secretary of Health and Human Services certain information with respect to provider terminations, and for other purposes.
HR 4588 Introduced February 23, 2016 by Gene Green (D-TX) To amend title XIX of the Social Security Act to provide the same level of Federal matching assistance for every State that chooses to expand Medicaid coverage to newly eligible individuals, regardless of when such expansion takes place.
HR 5273 Helping Hospitals Improve Patient Care Act of 2016 Introduced May 18, 2016 by Patrick Taberi (R-OH) To amend title XVIII of the Social Security Act to provide for regulatory relief under the Medicare program for certain providers of services and suppliers and increased transparency in hospital coding and enrollment data, and for other purposes.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 19, 2016.
Original Filing: 300814423.xml
Lobbying Issues
Medicare and Medicaid issues, Medigap issues, Medicare Advantage, CHIP reform, chronic care reform
HR 2488 Medicare Beneficiary Preservation of Choice Act of 2015 Introduced May 21, 2015 by Keith Rothfus (R-PA) This bill amends title XVIII (Medicare) of the Social Security Act to expand and modify enrollment and disenrollment options for Medicare Advantage (MA) eligible individuals. Specifically, the bill extends the annual period in which an individual enrolled in MA may elect to instead receive benefits under the original Medicare fee-for-service (FFS) program as well as elect to change qualified prescription drug coverage. Furthermore, any MA-eligible individual (weather or not enrolled in MA) may once per period change a previous election with respect to receiving benefits through MA or Medicare FFS, including changing from one MA plan to another. Unsolicited marketing during this period is prohibited.
HR 2895 Introduced June 25, 2015 by Mike Pompeo (R-KS) Medicare Patient Access to Cancer Treatment Act of 2015 To amend title XVIII of the Social Security Act to establish payment parity under the Medicare program for ambulatory cancer care services furnished in the hospital outpatient department and the physician office setting.
HR 3716 Introduced October 8, 2015 by Larry Bucshon (R-IN) To amend title XIX of the Social Security Act to require States to provide to the Secretary of Health and Human Services certain information with respect to provider terminations, and for other purposes.
HR 4588 Introduced February 23, 2016 by Gene Green (D-TX) To amend title XIX of the Social Security Act to provide the same level of Federal matching assistance for every State that chooses to expand Medicaid coverage to newly eligible individuals, regardless of when such expansion takes place.
HR 5273 Helping Hospitals Improve Patient Care Act of 2016 Introduced May 18, 2016 by Patrick Taberi (R-OH) To amend title XVIII of the Social Security Act to provide for regulatory relief under the Medicare program for certain providers of services and suppliers and increased transparency in hospital coding and enrollment data, and for other purposes.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300797943.xml
Lobbying Issues
Medicare issues, Patient Protection and Affordable Care Act (PPACA) issues and regulations, implementation issues, appropriations language, payment reform plan innovation, and cybersecurity.
H.R. 6 - Introduced May 19, 2015 by Rep. Fred Upton, The 21st Century Cures Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 28, 2016.
Original Filing: 300785581.xml
Lobbying Issues
Medicare issues, Patient Protection and Affordable Care Act (PPACA) issues and regulations, implementation issues, appropriations language, payment reform plan innovation, and cybersecurity.
H.R. 6 - Introduced May 19, 2015 by Rep. Fred Upton, The 21st Century Cures Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Oct. 19, 2015.
Original Filing: 300757498.xml
Lobbying Issues
Medicare issues, Patient Protection and Affordable Care Act (PPACA) issues and regulations, implementation issues, appropriations language, payment reform plan innovation, and cybersecurity.
H.R. 6 - Introduced May 19, 2015 by Rep. Fred Upton, The 21st Century Cures Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300740603.xml
Lobbying Issues
HR 1021 - "Protecting the Integrity of Medicare Act," to allow CMS the flexibility to rebid MAC contracts every 10 years rather than five.
S. 584 - "Better Efficiency and Administrative Simplification Act," which allows CMS the flexibility to rebid MAC contracts every 10 years rather than five.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300721735.xml
Lobbying Issues
H.R. 2 - Introduced Mar. 24, 2015 by Rep. Michael Burgess, Medicare Access and CHIP Reauthorization Act of 2015 to amend Title XVIII (Medicare) of the Social Security Act (SSAct) to: (1) remove sustainable growth rate (SGR) methodology from the determination of annual conversion factors in the formula for payment for physicians' services, and (2) revise the update in rates for 2015 and subsequent years. Directs the Secretary of Health and Human Services to establish a Merit-based Incentive Payment (MIP) system under which eligible professionals (including physicians, physician assistants, nurse practitioners, clinical nurse specialists, and certified registered nurse anesthetists) shall receive annual payment increases or decreases based on their performance. Requires specified incentive payments to eligible participants in an alternative payment model; Section Section 1874A(b)(1)(B) of the Social Security Act (42 U.S.C. 1395kk-1(b)(1)(B).
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, GuideWell Mutual Holding Corporation had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300701399.xml
Lobbying Issues
Providing CMS flexibility in bidding Medicare contracts
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2014
In Q3, GuideWell Mutual Holding Corporation did no lobbying for itself. The report was filed on Jan. 24, 2017.
Original Filing: 300858925.xml
2nd Quarter, 2014
In Q2, GuideWell Mutual Holding Corporation did no lobbying for itself. The report was filed on July 29, 2014.
Original Filing: 300671075.xml
1st Quarter, 2014
In Q1, GuideWell Mutual Holding Corporation did no lobbying for itself. The report was filed on July 24, 2014.
Original Filing: 300670723.xml
1st Quarter, 2014
In 1A, GuideWell Mutual Holding Corporation did no lobbying for itself. The report was filed on July 24, 2014.
Original Filing: 300670726.xml
1st Quarter, 2014
GuideWell Mutual Holding Corporation filed a lobbying registration on Jan. 7, 2014 for in-house lobbying efforts, effective Jan. 1, 2014.
Original Filing: 300611907.xml
Issue(s) they said they’d lobby about: Healthcare, Insurance, Pharmacy, Taxation .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...